カテゴリー： 世界, 医療/バイオ, QYResearch

注射用ペメトレキセド二ナトリウムのグローバル市場2023年：100mg/個、500mg/個

【英語タイトル】Global Pemetrexed Disodium for Injection Market Research Report 2023

QYResearchが出版した調査資料（QYR23MA8851）・商品コード：QYR23MA8851
・発行会社（調査会社）：QYResearch
・発行日：2023年3月（※2025年版があります。お問い合わせください。）
・ページ数：112
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥417,600見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥626,400見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥835,200見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

本調査レポートは世界の注射用ペメトレキセド二ナトリウム市場について調査・分析し、世界の注射用ペメトレキセド二ナトリウム市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（100mg/個、500mg/個）、用途別セグメント分析（病院、クリニック、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Lilly、Amneal Pharmaceuticals、APOTEX、Fresenius Kabi、Sandoz、Baxter、Biocon、Waverley Pharma、Accord Healthcare、Pfizer (Hospira)、Dr. Reddy's Laboratories、Nang Kuang Pharmaceutical、Eugia Pharma、Zydus Lifesciences、Jiangsu Hansoh Pharmaceutical、Qilu Pharmaceutical、Sichuan Huiyu Pharmaceutical、Kelun Pharmaceutical、Yangtze River Pharmaceutical Group、Jiangsu Aosaikang Pharmaceutical、Zhendong Group、Lianyungang Jaripharm Pharmaceutical、Jiangsu Simcere Pharmaceutical、Suzhou Erye Pharmaceutical、Shanghai Chemo Wanbang Biopharma、Hainan Jinrui Pharmaceutical、Dezhou Deyao Pharmaceutical、Nanjing Pharmaceutical Factory、Beijing Xiehe Pharmaceutical、Suzhou Thery Pharmaceuticalなどが含まれています。世界の注射用ペメトレキセド二ナトリウム市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、注射用ペメトレキセド二ナトリウム市場規模を推定する際に考慮しました。

・注射用ペメトレキセド二ナトリウム市場の概要
- 製品の定義
- 注射用ペメトレキセド二ナトリウムのタイプ別セグメント
- 世界の注射用ペメトレキセド二ナトリウム市場規模：タイプ別分析（100mg/個、500mg/個）
- 注射用ペメトレキセド二ナトリウムの用途別セグメント
- 世界の注射用ペメトレキセド二ナトリウム市場規模：用途別分析（病院、クリニック、その他）
- 世界の注射用ペメトレキセド二ナトリウム市場規模予測（2018年-2029年）
- 注射用ペメトレキセド二ナトリウムの平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 注射用ペメトレキセド二ナトリウム市場の競争状況およびトレンド

・注射用ペメトレキセド二ナトリウムの地域別市場規模
- 北米の注射用ペメトレキセド二ナトリウム市場規模（2018年-2029年）
- アメリカの注射用ペメトレキセド二ナトリウム市場規模（2018年-2029年）
- ヨーロッパの注射用ペメトレキセド二ナトリウム市場規模（2018年-2029年）
- アジア太平洋の注射用ペメトレキセド二ナトリウム市場規模（2018年-2029年）
- 中国の注射用ペメトレキセド二ナトリウム市場規模（2018年-2029年）
- 日本の注射用ペメトレキセド二ナトリウム市場規模（2018年-2029年）
- 韓国の注射用ペメトレキセド二ナトリウム市場規模（2018年-2029年）
- インドの注射用ペメトレキセド二ナトリウム市場規模（2018年-2029年）
- オーストラリアの注射用ペメトレキセド二ナトリウム市場規模（2018年-2029年）
- 中南米の注射用ペメトレキセド二ナトリウム市場規模（2018年-2029年）
- 中東・アフリカの注射用ペメトレキセド二ナトリウム市場規模（2018年-2029年）

・タイプ別セグメント：100mg/個、500mg/個
- 世界の注射用ペメトレキセド二ナトリウムのタイプ別販売量（2018年-2023年）
- 世界の注射用ペメトレキセド二ナトリウムのタイプ別売上（2018年-2023年）
- 世界の注射用ペメトレキセド二ナトリウムのタイプ別価格

・用途別セグメント：病院、クリニック、その他
- 世界の注射用ペメトレキセド二ナトリウムの用途別販売量（2018年-2023年）
- 世界の注射用ペメトレキセド二ナトリウムの用途別売上（2018年-2023年）
- 世界の注射用ペメトレキセド二ナトリウムの用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Lilly、Amneal Pharmaceuticals、APOTEX、Fresenius Kabi、Sandoz、Baxter、Biocon、Waverley Pharma、Accord Healthcare、Pfizer (Hospira)、Dr. Reddy's Laboratories、Nang Kuang Pharmaceutical、Eugia Pharma、Zydus Lifesciences、Jiangsu Hansoh Pharmaceutical、Qilu Pharmaceutical、Sichuan Huiyu Pharmaceutical、Kelun Pharmaceutical、Yangtze River Pharmaceutical Group、Jiangsu Aosaikang Pharmaceutical、Zhendong Group、Lianyungang Jaripharm Pharmaceutical、Jiangsu Simcere Pharmaceutical、Suzhou Erye Pharmaceutical、Shanghai Chemo Wanbang Biopharma、Hainan Jinrui Pharmaceutical、Dezhou Deyao Pharmaceutical、Nanjing Pharmaceutical Factory、Beijing Xiehe Pharmaceutical、Suzhou Thery Pharmaceutical

・産業チェーンと販売チャネルの分析
- 注射用ペメトレキセド二ナトリウム産業チェーン分析
- 注射用ペメトレキセド二ナトリウムの主要原材料
- 注射用ペメトレキセド二ナトリウムの販売チャネル
- 注射用ペメトレキセド二ナトリウムのディストリビューター
- 注射用ペメトレキセド二ナトリウムの主要顧客

・注射用ペメトレキセド二ナトリウム市場ダイナミクス
- 注射用ペメトレキセド二ナトリウムの業界動向
- 注射用ペメトレキセド二ナトリウム市場の成長ドライバ、課題、阻害要因

・調査成果および結論

・調査方法とデータソース

Highlights
The global Pemetrexed Disodium for Injection market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Pemetrexed Disodium for Injection is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Pemetrexed Disodium for Injection is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Pemetrexed Disodium for Injection include Lilly, Amneal Pharmaceuticals, APOTEX, Fresenius Kabi, Sandoz, Baxter, Biocon, Waverley Pharma and Accord Healthcare, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pemetrexed Disodium for Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pemetrexed Disodium for Injection.
The Pemetrexed Disodium for Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Pemetrexed Disodium for Injection market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pemetrexed Disodium for Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Lilly
Amneal Pharmaceuticals
APOTEX
Fresenius Kabi
Sandoz
Baxter
Biocon
Waverley Pharma
Accord Healthcare
Pfizer (Hospira)
Dr. Reddy’s Laboratories
Nang Kuang Pharmaceutical
Eugia Pharma
Zydus Lifesciences
Jiangsu Hansoh Pharmaceutical
Qilu Pharmaceutical
Sichuan Huiyu Pharmaceutical
Kelun Pharmaceutical
Yangtze River Pharmaceutical Group
Jiangsu Aosaikang Pharmaceutical
Zhendong Group
Lianyungang Jaripharm Pharmaceutical
Jiangsu Simcere Pharmaceutical
Suzhou Erye Pharmaceutical
Shanghai Chemo Wanbang Biopharma
Hainan Jinrui Pharmaceutical
Dezhou Deyao Pharmaceutical
Nanjing Pharmaceutical Factory
Beijing Xiehe Pharmaceutical
Suzhou Thery Pharmaceutical
Segment by Type
100mg/Pcs
500mg/Pcs
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pemetrexed Disodium for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pemetrexed Disodium for Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Pemetrexed Disodium for Injection Market Overview
1.1 Product Overview and Scope of Pemetrexed Disodium for Injection
1.2 Pemetrexed Disodium for Injection Segment by Type
1.2.1 Global Pemetrexed Disodium for Injection Market Value Comparison by Type (2023-2029)
1.2.2 100mg/Pcs
1.2.3 500mg/Pcs
1.3 Pemetrexed Disodium for Injection Segment by Application
1.3.1 Global Pemetrexed Disodium for Injection Market Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Pemetrexed Disodium for Injection Market Size Estimates and Forecasts
1.4.1 Global Pemetrexed Disodium for Injection Revenue 2018-2029
1.4.2 Global Pemetrexed Disodium for Injection Sales 2018-2029
1.4.3 Global Pemetrexed Disodium for Injection Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Pemetrexed Disodium for Injection Market Competition by Manufacturers
2.1 Global Pemetrexed Disodium for Injection Sales Market Share by Manufacturers (2018-2023)
2.2 Global Pemetrexed Disodium for Injection Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Pemetrexed Disodium for Injection Average Price by Manufacturers (2018-2023)
2.4 Global Pemetrexed Disodium for Injection Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Pemetrexed Disodium for Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pemetrexed Disodium for Injection, Product Type & Application
2.7 Pemetrexed Disodium for Injection Market Competitive Situation and Trends
2.7.1 Pemetrexed Disodium for Injection Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pemetrexed Disodium for Injection Players Market Share by Revenue
2.7.3 Global Pemetrexed Disodium for Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pemetrexed Disodium for Injection Retrospective Market Scenario by Region
3.1 Global Pemetrexed Disodium for Injection Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Pemetrexed Disodium for Injection Global Pemetrexed Disodium for Injection Sales by Region: 2018-2029
3.2.1 Global Pemetrexed Disodium for Injection Sales by Region: 2018-2023
3.2.2 Global Pemetrexed Disodium for Injection Sales by Region: 2024-2029
3.3 Global Pemetrexed Disodium for Injection Global Pemetrexed Disodium for Injection Revenue by Region: 2018-2029
3.3.1 Global Pemetrexed Disodium for Injection Revenue by Region: 2018-2023
3.3.2 Global Pemetrexed Disodium for Injection Revenue by Region: 2024-2029
3.4 North America Pemetrexed Disodium for Injection Market Facts & Figures by Country
3.4.1 North America Pemetrexed Disodium for Injection Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Pemetrexed Disodium for Injection Sales by Country (2018-2029)
3.4.3 North America Pemetrexed Disodium for Injection Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pemetrexed Disodium for Injection Market Facts & Figures by Country
3.5.1 Europe Pemetrexed Disodium for Injection Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Pemetrexed Disodium for Injection Sales by Country (2018-2029)
3.5.3 Europe Pemetrexed Disodium for Injection Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pemetrexed Disodium for Injection Market Facts & Figures by Country
3.6.1 Asia Pacific Pemetrexed Disodium for Injection Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Pemetrexed Disodium for Injection Sales by Country (2018-2029)
3.6.3 Asia Pacific Pemetrexed Disodium for Injection Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Pemetrexed Disodium for Injection Market Facts & Figures by Country
3.7.1 Latin America Pemetrexed Disodium for Injection Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Pemetrexed Disodium for Injection Sales by Country (2018-2029)
3.7.3 Latin America Pemetrexed Disodium for Injection Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Pemetrexed Disodium for Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Pemetrexed Disodium for Injection Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Pemetrexed Disodium for Injection Sales by Country (2018-2029)
3.8.3 Middle East and Africa Pemetrexed Disodium for Injection Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pemetrexed Disodium for Injection Sales by Type (2018-2029)
4.1.1 Global Pemetrexed Disodium for Injection Sales by Type (2018-2023)
4.1.2 Global Pemetrexed Disodium for Injection Sales by Type (2024-2029)
4.1.3 Global Pemetrexed Disodium for Injection Sales Market Share by Type (2018-2029)
4.2 Global Pemetrexed Disodium for Injection Revenue by Type (2018-2029)
4.2.1 Global Pemetrexed Disodium for Injection Revenue by Type (2018-2023)
4.2.2 Global Pemetrexed Disodium for Injection Revenue by Type (2024-2029)
4.2.3 Global Pemetrexed Disodium for Injection Revenue Market Share by Type (2018-2029)
4.3 Global Pemetrexed Disodium for Injection Price by Type (2018-2029)
5 Segment by Application
5.1 Global Pemetrexed Disodium for Injection Sales by Application (2018-2029)
5.1.1 Global Pemetrexed Disodium for Injection Sales by Application (2018-2023)
5.1.2 Global Pemetrexed Disodium for Injection Sales by Application (2024-2029)
5.1.3 Global Pemetrexed Disodium for Injection Sales Market Share by Application (2018-2029)
5.2 Global Pemetrexed Disodium for Injection Revenue by Application (2018-2029)
5.2.1 Global Pemetrexed Disodium for Injection Revenue by Application (2018-2023)
5.2.2 Global Pemetrexed Disodium for Injection Revenue by Application (2024-2029)
5.2.3 Global Pemetrexed Disodium for Injection Revenue Market Share by Application (2018-2029)
5.3 Global Pemetrexed Disodium for Injection Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Lilly
6.1.1 Lilly Corporation Information
6.1.2 Lilly Description and Business Overview
6.1.3 Lilly Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Lilly Pemetrexed Disodium for Injection Product Portfolio
6.1.5 Lilly Recent Developments/Updates
6.2 Amneal Pharmaceuticals
6.2.1 Amneal Pharmaceuticals Corporation Information
6.2.2 Amneal Pharmaceuticals Description and Business Overview
6.2.3 Amneal Pharmaceuticals Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Amneal Pharmaceuticals Pemetrexed Disodium for Injection Product Portfolio
6.2.5 Amneal Pharmaceuticals Recent Developments/Updates
6.3 APOTEX
6.3.1 APOTEX Corporation Information
6.3.2 APOTEX Description and Business Overview
6.3.3 APOTEX Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.3.4 APOTEX Pemetrexed Disodium for Injection Product Portfolio
6.3.5 APOTEX Recent Developments/Updates
6.4 Fresenius Kabi
6.4.1 Fresenius Kabi Corporation Information
6.4.2 Fresenius Kabi Description and Business Overview
6.4.3 Fresenius Kabi Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Fresenius Kabi Pemetrexed Disodium for Injection Product Portfolio
6.4.5 Fresenius Kabi Recent Developments/Updates
6.5 Sandoz
6.5.1 Sandoz Corporation Information
6.5.2 Sandoz Description and Business Overview
6.5.3 Sandoz Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sandoz Pemetrexed Disodium for Injection Product Portfolio
6.5.5 Sandoz Recent Developments/Updates
6.6 Baxter
6.6.1 Baxter Corporation Information
6.6.2 Baxter Description and Business Overview
6.6.3 Baxter Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Baxter Pemetrexed Disodium for Injection Product Portfolio
6.6.5 Baxter Recent Developments/Updates
6.7 Biocon
6.6.1 Biocon Corporation Information
6.6.2 Biocon Description and Business Overview
6.6.3 Biocon Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Biocon Pemetrexed Disodium for Injection Product Portfolio
6.7.5 Biocon Recent Developments/Updates
6.8 Waverley Pharma
6.8.1 Waverley Pharma Corporation Information
6.8.2 Waverley Pharma Description and Business Overview
6.8.3 Waverley Pharma Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Waverley Pharma Pemetrexed Disodium for Injection Product Portfolio
6.8.5 Waverley Pharma Recent Developments/Updates
6.9 Accord Healthcare
6.9.1 Accord Healthcare Corporation Information
6.9.2 Accord Healthcare Description and Business Overview
6.9.3 Accord Healthcare Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Accord Healthcare Pemetrexed Disodium for Injection Product Portfolio
6.9.5 Accord Healthcare Recent Developments/Updates
6.10 Pfizer (Hospira)
6.10.1 Pfizer (Hospira) Corporation Information
6.10.2 Pfizer (Hospira) Description and Business Overview
6.10.3 Pfizer (Hospira) Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Pfizer (Hospira) Pemetrexed Disodium for Injection Product Portfolio
6.10.5 Pfizer (Hospira) Recent Developments/Updates
6.11 Dr. Reddy’s Laboratories
6.11.1 Dr. Reddy’s Laboratories Corporation Information
6.11.2 Dr. Reddy’s Laboratories Pemetrexed Disodium for Injection Description and Business Overview
6.11.3 Dr. Reddy’s Laboratories Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Dr. Reddy’s Laboratories Pemetrexed Disodium for Injection Product Portfolio
6.11.5 Dr. Reddy’s Laboratories Recent Developments/Updates
6.12 Nang Kuang Pharmaceutical
6.12.1 Nang Kuang Pharmaceutical Corporation Information
6.12.2 Nang Kuang Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.12.3 Nang Kuang Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Nang Kuang Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.12.5 Nang Kuang Pharmaceutical Recent Developments/Updates
6.13 Eugia Pharma
6.13.1 Eugia Pharma Corporation Information
6.13.2 Eugia Pharma Pemetrexed Disodium for Injection Description and Business Overview
6.13.3 Eugia Pharma Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Eugia Pharma Pemetrexed Disodium for Injection Product Portfolio
6.13.5 Eugia Pharma Recent Developments/Updates
6.14 Zydus Lifesciences
6.14.1 Zydus Lifesciences Corporation Information
6.14.2 Zydus Lifesciences Pemetrexed Disodium for Injection Description and Business Overview
6.14.3 Zydus Lifesciences Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Zydus Lifesciences Pemetrexed Disodium for Injection Product Portfolio
6.14.5 Zydus Lifesciences Recent Developments/Updates
6.15 Jiangsu Hansoh Pharmaceutical
6.15.1 Jiangsu Hansoh Pharmaceutical Corporation Information
6.15.2 Jiangsu Hansoh Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.15.3 Jiangsu Hansoh Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Jiangsu Hansoh Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.15.5 Jiangsu Hansoh Pharmaceutical Recent Developments/Updates
6.16 Qilu Pharmaceutical
6.16.1 Qilu Pharmaceutical Corporation Information
6.16.2 Qilu Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.16.3 Qilu Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Qilu Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.16.5 Qilu Pharmaceutical Recent Developments/Updates
6.17 Sichuan Huiyu Pharmaceutical
6.17.1 Sichuan Huiyu Pharmaceutical Corporation Information
6.17.2 Sichuan Huiyu Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.17.3 Sichuan Huiyu Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Sichuan Huiyu Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.17.5 Sichuan Huiyu Pharmaceutical Recent Developments/Updates
6.18 Kelun Pharmaceutical
6.18.1 Kelun Pharmaceutical Corporation Information
6.18.2 Kelun Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.18.3 Kelun Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Kelun Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.18.5 Kelun Pharmaceutical Recent Developments/Updates
6.19 Yangtze River Pharmaceutical Group
6.19.1 Yangtze River Pharmaceutical Group Corporation Information
6.19.2 Yangtze River Pharmaceutical Group Pemetrexed Disodium for Injection Description and Business Overview
6.19.3 Yangtze River Pharmaceutical Group Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Yangtze River Pharmaceutical Group Pemetrexed Disodium for Injection Product Portfolio
6.19.5 Yangtze River Pharmaceutical Group Recent Developments/Updates
6.20 Jiangsu Aosaikang Pharmaceutical
6.20.1 Jiangsu Aosaikang Pharmaceutical Corporation Information
6.20.2 Jiangsu Aosaikang Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.20.3 Jiangsu Aosaikang Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Jiangsu Aosaikang Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.20.5 Jiangsu Aosaikang Pharmaceutical Recent Developments/Updates
6.21 Zhendong Group
6.21.1 Zhendong Group Corporation Information
6.21.2 Zhendong Group Pemetrexed Disodium for Injection Description and Business Overview
6.21.3 Zhendong Group Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Zhendong Group Pemetrexed Disodium for Injection Product Portfolio
6.21.5 Zhendong Group Recent Developments/Updates
6.22 Lianyungang Jaripharm Pharmaceutical
6.22.1 Lianyungang Jaripharm Pharmaceutical Corporation Information
6.22.2 Lianyungang Jaripharm Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.22.3 Lianyungang Jaripharm Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Lianyungang Jaripharm Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.22.5 Lianyungang Jaripharm Pharmaceutical Recent Developments/Updates
6.23 Jiangsu Simcere Pharmaceutical
6.23.1 Jiangsu Simcere Pharmaceutical Corporation Information
6.23.2 Jiangsu Simcere Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.23.3 Jiangsu Simcere Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Jiangsu Simcere Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.23.5 Jiangsu Simcere Pharmaceutical Recent Developments/Updates
6.24 Suzhou Erye Pharmaceutical
6.24.1 Suzhou Erye Pharmaceutical Corporation Information
6.24.2 Suzhou Erye Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.24.3 Suzhou Erye Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Suzhou Erye Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.24.5 Suzhou Erye Pharmaceutical Recent Developments/Updates
6.25 Shanghai Chemo Wanbang Biopharma
6.25.1 Shanghai Chemo Wanbang Biopharma Corporation Information
6.25.2 Shanghai Chemo Wanbang Biopharma Pemetrexed Disodium for Injection Description and Business Overview
6.25.3 Shanghai Chemo Wanbang Biopharma Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Shanghai Chemo Wanbang Biopharma Pemetrexed Disodium for Injection Product Portfolio
6.25.5 Shanghai Chemo Wanbang Biopharma Recent Developments/Updates
6.26 Hainan Jinrui Pharmaceutical
6.26.1 Hainan Jinrui Pharmaceutical Corporation Information
6.26.2 Hainan Jinrui Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.26.3 Hainan Jinrui Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.26.4 Hainan Jinrui Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.26.5 Hainan Jinrui Pharmaceutical Recent Developments/Updates
6.27 Dezhou Deyao Pharmaceutical
6.27.1 Dezhou Deyao Pharmaceutical Corporation Information
6.27.2 Dezhou Deyao Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.27.3 Dezhou Deyao Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.27.4 Dezhou Deyao Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.27.5 Dezhou Deyao Pharmaceutical Recent Developments/Updates
6.28 Nanjing Pharmaceutical Factory
6.28.1 Nanjing Pharmaceutical Factory Corporation Information
6.28.2 Nanjing Pharmaceutical Factory Pemetrexed Disodium for Injection Description and Business Overview
6.28.3 Nanjing Pharmaceutical Factory Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.28.4 Nanjing Pharmaceutical Factory Pemetrexed Disodium for Injection Product Portfolio
6.28.5 Nanjing Pharmaceutical Factory Recent Developments/Updates
6.29 Beijing Xiehe Pharmaceutical
6.29.1 Beijing Xiehe Pharmaceutical Corporation Information
6.29.2 Beijing Xiehe Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.29.3 Beijing Xiehe Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.29.4 Beijing Xiehe Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.29.5 Beijing Xiehe Pharmaceutical Recent Developments/Updates
6.30 Suzhou Thery Pharmaceutical
6.30.1 Suzhou Thery Pharmaceutical Corporation Information
6.30.2 Suzhou Thery Pharmaceutical Pemetrexed Disodium for Injection Description and Business Overview
6.30.3 Suzhou Thery Pharmaceutical Pemetrexed Disodium for Injection Sales, Revenue and Gross Margin (2018-2023)
6.30.4 Suzhou Thery Pharmaceutical Pemetrexed Disodium for Injection Product Portfolio
6.30.5 Suzhou Thery Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pemetrexed Disodium for Injection Industry Chain Analysis
7.2 Pemetrexed Disodium for Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pemetrexed Disodium for Injection Production Mode & Process
7.4 Pemetrexed Disodium for Injection Sales and Marketing
7.4.1 Pemetrexed Disodium for Injection Sales Channels
7.4.2 Pemetrexed Disodium for Injection Distributors
7.5 Pemetrexed Disodium for Injection Customers
8 Pemetrexed Disodium for Injection Market Dynamics
8.1 Pemetrexed Disodium for Injection Industry Trends
8.2 Pemetrexed Disodium for Injection Market Drivers
8.3 Pemetrexed Disodium for Injection Market Challenges
8.4 Pemetrexed Disodium for Injection Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer


※参考情報

注射用ペメトレキセド二ナトリウムは、主に癌治療に用いられる抗癌剤です。ペメトレキセドは、抗葉酸剤として知られ、細胞増殖を抑制する作用を持ちます。この薬剤は、特に非小細胞肺癌や悪性胸膜中皮腫などの治療に使用されています。

ペメトレキセドの主な特徴は、その作用機序にあります。葉酸は細胞が DNA 合成を行うために不可欠な成分ですが、ペメトレキセドは葉酸と同様の構造を持っており、葉酸の代謝経路を阻害します。これにより、癌細胞の増殖を抑えることができます。さらに、ペメトレキセドは、腫瘍細胞の増殖速度が速い場合に特に効果的であるため、高い抗腫瘍効果が期待されます。

ペメトレキセドは、主に静脈内注射によって投与されます。これにより、薬剤が迅速に血流に乗り、全身に分布します。治療は、低用量の化学療法と組み合わせて行われることが多く、他の抗癌剤との併用によっても効果が向上する場合があります。

この薬剤の用途は、特に非小細胞肺癌や悪性胸膜中皮腫の治療に限られています。非小細胞肺癌は肺癌の中でも最も一般的な形態であり、患者の治療選択肢を増やすために、ペメトレキセドが使用されます。悪性胸膜中皮腫は、アスベストによる曝露が原因となることが多く、治療が困難な病気ですが、ペメトレキセドの投与により患者の生存期間を延ばす可能性があります。

ペメトレキセドの投与にあたっては、副作用も考慮する必要があります。一般的な副作用としては、疲労感、吐き気、食欲不振、貧血、白血球減少などが見られます。特に、血液に関連する副作用は注意が必要であり、適切なモニタリングが求められます。また、患者によっては、重篤なアレルギー反応や呼吸困難が生じることもあり、使用にあたっては医師の監視が重要です。

関連技術としては、ペメトレキセドを用いた治療における個別化医療の進展が挙げられます。ジェノム解析によって患者の腫瘍の特性を理解し、それに最適な治療法を選択することで、より効果的な治療が可能となります。これにより、患者一人ひとりの治療効果を最大化することが期待されます。

また、ペメトレキセドに関する研究は今後も継続されており、新たな適応症の検討や治療法の組み合わせについての研究が進められています。可能性としては、免疫療法や分子標的療法との併用研究が進行中であり、これによりさらに高い効果が得られることが期待されています。

このように、注射用ペメトレキセド二ナトリウムは、癌治療において重要な役割を持つ薬剤であり、その独自の作用機序と併用療法によって、多くの患者に有益な選択肢を提供しています。医学が進歩する中で、ペメトレキセドの利用が広がり、より多くの患者がその恩恵を受けることが期待されます。今後の研究や臨床試験を通じて、ペメトレキセドの新たな適応症や効果的な使用法が明らかになり、癌治療の更なる進展につながることが望まれます。


★調査レポート[注射用ペメトレキセド二ナトリウムのグローバル市場2023年：100mg/個、500mg/個] (コード：QYR23MA8851)販売に関する免責事項を必ずご確認ください。
★調査レポート[注射用ペメトレキセド二ナトリウムのグローバル市場2023年：100mg/個、500mg/個]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のフォスタマチニブ錠剤市場展望2025年-2031年
  • グラゾプレビルの世界市場2025-2031
  • エノキサパリンナトリウムAPI・製剤の世界市場2025-2031

    • ◆H&Iグローバルリサーチのお客様（例）◆